These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 21366643)

  • 1. Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology.
    des Champs-Bro B; Leroy-Cotteau A; Mazingue F; Pasquier F; François N; Corm S; Lemaitre L; Poulain D; Yakoub-Agha I; Alfandari S; Sendid B
    J Clin Pharm Ther; 2011 Apr; 36(2):152-60. PubMed ID: 21366643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
    Maertens J
    Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
    Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
    Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis.
    Kaya Z; Gursel T; Kocak U; Aral YZ; Kalkanci A; Albayrak M
    Pediatr Blood Cancer; 2009 Apr; 52(4):470-5. PubMed ID: 19058205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies.
    Hoenigl M; Zollner-Schwetz I; Sill H; Linkesch W; Lass-Flörl C; Schnedl WJ; Krause R
    Mycoses; 2011 Sep; 54(5):454-9. PubMed ID: 20406398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999.
    Lortholary O; Charlemagne A; Bastides F; Chevalier P; Datry A; Gonzalves MF; Michel G; Tilleul P; Veber B; Herbrecht R
    J Antimicrob Chemother; 2004 Aug; 54(2):456-64. PubMed ID: 15231769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prophylaxis and treatment of invasive fungal infection in neutropenic patients].
    Vallejo C; Rovira M
    Rev Esp Quimioter; 2010 Dec; 23(4):177-83. PubMed ID: 21191555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
    Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
    Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies.
    Hoenigl M; Strenger V; Buzina W; Valentin T; Koidl C; Wölfler A; Seeber K; Valentin A; Strohmeier AT; Zollner-Schwetz I; Raggam RB; Urban C; Lass-Flörl C; Linkesch W; Krause R
    J Antimicrob Chemother; 2012 Aug; 67(8):2029-33. PubMed ID: 22566591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in antifungal prophylaxis and empiric therapy in patients with hematologic malignancies.
    Murali S; Langston A
    Transpl Infect Dis; 2009 Dec; 11(6):480-90. PubMed ID: 19725908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination.
    Trenschel R; Peceny R; Runde V; Elmaagacli A; Dermoumi H; Heintschel von Heinegg E; Müller KD; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2000 Nov; 26(9):993-7. PubMed ID: 11100279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy.
    Cornely OA; Aversa F; Cook P; Jones B; Michallet M; Shea T; Vallejo C
    Eur J Haematol; 2011 Oct; 87(4):289-301. PubMed ID: 21752098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hema e-Chart registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections.
    Nosari AM; Caira M; Pioltelli ML; Fanci R; Bonini A; Cattaneo C; Castagnola C; Capalbo SF; De Fabritiis P; Mettivier V; Morselli M; Pastore D; Aversa F; Rossi G; Pagano L;
    Clin Microbiol Infect; 2013 Aug; 19(8):757-62. PubMed ID: 23279327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal therapy in patients with hematological malignancies: how to avoid overtreatment?
    Cherif H; Kalin M; Björkholm M
    Eur J Haematol; 2006 Oct; 77(4):288-92. PubMed ID: 16856930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Invasive fungal infection in haematology patients].
    Vallejo Llamas JC; Ruiz-Camps I
    Enferm Infecc Microbiol Clin; 2012 Nov; 30(9):572-9. PubMed ID: 23079614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive fungal infections in pediatric patients with hematologic malignancies receiving oral amphotericin B solution and early intravenous administration of fluconazole.
    Watanabe N; Matsumoto K; Kojima S; Kato K
    J Pediatr Hematol Oncol; 2011 May; 33(4):270-5. PubMed ID: 21464763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review.
    Pechlivanoglou P; Le HH; Daenen S; Snowden JA; Postma MJ
    J Antimicrob Chemother; 2014 Jan; 69(1):1-11. PubMed ID: 23975736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
    Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR
    Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal treatment strategies in high risk patients.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empiric vs. preemptive antifungal treatment: an appraisal of treatment strategies in haematological patients.
    Rieger CT; Ostermann H
    Mycoses; 2008; 51 Suppl 1():31-4. PubMed ID: 18471159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.